Aspirin and Cancer

Journal of the American College of Cardiology

Volumn 68, Issue 9, 2016, Pages 967-976

  Patrignani, Paola ^a   Patrono, Carlo ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

chemoprevention; colorectal neoplasms; cyclooxygenase 1; nonsteroidal anti inflammatory agents; platelet activation; prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; ANTITHROMBOCYTIC AGENT;

ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BILIARY TRACT CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; CONCEPTUAL FRAMEWORK; DIGESTIVE SYSTEM CANCER; DISTANT METASTASIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; ESOPHAGUS CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LOW DRUG DOSE; NEOPLASM; NONHUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH CANCER; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; PROCEDURES;

ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION;

EID: 84995933501     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.083     Document Type: Review

References (52)

1. 1 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
2. 2 Roffi, M., Patrono, C., Collet, J.P., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37 (2016), 267–315.
3. 3 Parekh, A.K., Galloway, J.M., Hong, Y., et al. Aspirin in the secondary prevention of cardiovascular disease. N Engl J Med 368 (2013), 204–205.
4. 4 Patrono, C., The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 66 (2015), 74–85.
5. 5 Patrono, C., Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both or neither?. Eur Heart J 34 (2013), 3403–3411.
6. 6 Vandvik, P.O., Lincoff, A.M., Gore, J.M., et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e637S–e668S.
7. 7 Authors/Task Force Members, Perk, J., De Backer, G., Gohike, H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 33 (2012), 1635–1701.
8. 8 Bibbins-Domingo, K., on behalf of the U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164 (2016), 836–845.
9. 9 Thun, M.J., Jacobs, E.J., Patrono, C., The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9 (2012), 259–267.
10. 10 Kune, G.A., Kune, S., Watson, L.F., Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48 (1988), 4399–4404.
11. 11 Algra, A.M., Rothwell, P.M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13 (2012), 518–527.
12. 12 Cole, B.F., Logan, R.F., Halabi, S., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101 (2009), 256–266.
13. 13 Burn, J., Bishop, D.T., Mecklin, J.P., et al., for the CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359 (2008), 2567–2578.
14. 14 Burn, J., Gerdes, A.M., Macrae, F., et al., for the CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378 (2011), 2081–2087.
15. 15 Rothwell, P.M., Price, J.F., Fowkes, F.G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379 (2012), 1602–1612.
16. 16 Thun, M.J., Henley, S.J., Patrono, C., Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002), 252–266.
17. 17 Patrono, C., Rocca, B., Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 28 (2008), s25–s32.
18. 18 Coxib and Traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
19. 19 Institute of Genetic Medicine, Newcastle University, and International Center for Life. CaPP3 Cancer Prevention Programme. Available at: http://www.capp3.org. Accessed June 20, 2016.
20. 20 Flossmann, E., Rothwell, P.M., for the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 (2007), 1603–1613.
21. 21 Rothwell, P.M., Fowkes, F.G., Belch, J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (2011), 31–41.
22. 22 Rothwell, P.M., Wilson, M., Price, J.F., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601.
23. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325 (1991), 1137–1141.
24. 24 Cook, N.R., Lee, I.M., Zhang, S.M., et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159 (2013), 77–85.
25. 25 Patrignani, P., Filabozzi, P., Patrono, C., Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982), 1366–1372.
26. 26 Patrignani, P., Tacconelli, S., Piazuelo, E., et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost 12 (2014), 1320–1330.
27. 27 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
28. 28 Dovizio, M., Bruno, A., Tacconelli, S., et al. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191 (2013), 39–65.
29. 29 Patrono, C., Patrignani, P., García Rodríguez, L.A., Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108 (2001), 7–13.
30. 30 Pinckard, R.N., Hawkins, D., Farr, R.S., In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 219 (1968), 68–69.
31. 31 Dovizio, M., Maier, T.J., Alberti, S., et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol 84 (2013), 25–40.
32. 32 Aldrovandi, M., Hammond, V.J., Podmore, H., et al. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. J Lipid Res 54 (2013), 3085–3097.
33. 33 Ulrych, T., Böhm, A., Polzin, A., et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 9 (2011), 790–798.
34. 34 Coppinger, J.A., Cagney, G., Toomey, S., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103 (2004), 2096–2104.
35. 35 Heijnen, H.F., Schiel, A.E., Fijnheer, R., et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94 (1999), 3791–3799.
36. 36 Valadi, H., Ekström, K., Bossios, A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9 (2007), 654–659.
37. 37 Menter, D.G., Dubois, R.N., Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol, 2012, 2012, 723419.
38. 38 Zelenay, S., van der Veen, A.G., Böttcher, J.P., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.
39. 39 Chulada, P.C., Thompson, M.B., Mahler, J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60 (2000), 4705–4708.
40. 40 Myung, S.J., Rerko, R.M., Yan, M., et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 103 (2006), 12098–12102.
41. 41 Eberhart, C.E., Coffey, R.J., Radhika, A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994), 1183–1188.
42. 2 levels and ribosomal protein S6 phosphorylation by low-dose aspirin in subjects undergoing colorectal cancer screening. Gastroenterology, 150(Suppl 1), 2016, S211.
43. 43 Gay, L.J., Felding-Habermann, B., Contribution of platelets to tumour metastasis. Nat Rev Cancer 11 (2011), 123–134.
44. 44 Labelle, M., Begum, S., Hynes, R.O., Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20 (2011), 576–590.
45. 45 Guillem-Llobat, P., Dovizio, M., Bruno, A., et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 2016 Apr 8 [E-pub ahead of print].
46. 46 Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
47. 47 Cuzick, J., Thorat, M.A., Bosetti, C., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26 (2015), 47–57.
48. 48 U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 146 (2007), 361–364.
49. 49 Halvorsen, S., Andreotti, F., ten Berg, J.M., et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 64 (2014), 319–327.
50. 50 Chan, A.T., Ladabaum, U., Where do we stand with aspirin for the prevention of colorectal cancer? The USPTF recommendations. Gastroenterology 150 (2016), 14–18.
51. 51 Liao, X., Lochhead, P., Nishihara, R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367 (2012), 1596–1606.
52. 52 Nan, H., Hutter, C.M., Lin, Y., et al., for the CCFR and GECCO. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313 (2015), 1133–1142.